Impact of Abiraterone Acetate plus Prednisone or Enzalutamide on Patient-reported Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer: Final 12-mo Analysis from the Observational AQUARiUS Study
Uro-Oncology
COMMENTED
Related content
Uro-Oncology
Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer
Eur Urol.
Isaacsson Velho P, Fu W, Wang H, Mirkheshti N, Qazi F, Lima FAS, Shaukat F, Carducci MA, Denmeade SR, Paller CJ, Markowski MC, Marshall CH, Eisenberger MA,
Antonarakis ES
doi: 10.1016/j.eururo.
Uro-Oncology
Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer
doi: 10.1016/j.eururo.2018.11.016.
Uro-Oncology
Impact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trials
Prostate Cancer Prostatic Dis
Tombal BF, Freedland SJ, Armstrong AJ, Beer TM, Stenzl A, Sternberg CN, Hussain M, Ganguli A, Ramaswamy K, Bhadauria H, Ivanescu C, Turnbull J, Holmstrom S, Saad F
doi: 10.1038/s41391-021-00447-9
Uro-Oncology
Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide
Prostate.
Lolli C, De Lisi D, Conteduca V, Gurioli G, Scarpi E, Schepisi G, Ravaglia G, Menna C, Farolfi A, Altavilla A, Burgio SL, Tonini G, Santini D, De Giorgi U
doi: 10.1002/pros.23804.
Uro-Oncology
Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study
J Clin Oncol
Chi KN, Chowdhury S, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, Juárez A, Merseburger AS, Özgüroğlu M, Uemura H, Ye D, Brookman-May S, Mundle SD, McCarthy SA, Larsen JS, Sun W, Bevans KB, Zhang K, Bandyopadhyay N, Agarwal N
doi: 10.1200/JCO.20.03488
Uro-Oncology
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Prostate Cancer Prostatic Dis
Wenzel M, Nocera L, Collà Ruvolo C, Würnschimmel C, Tian Z, Shariat SF, Saad F, Tilki D, Graefen M, Kluth LA, Briganti A, Mandel P, Montorsi F, Chun FKH, Karakiewicz PI
doi: 10.1038/s41391-021-00395-4
Uro-Oncology
Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial
Prostate Cancer Prostatic Dis
Penson DF, Armstrong AJ, Concepcion RS, Agarwal N, Olsson CA, Karsh LI, Dunshee CJ, Duggan W, Shen Q, Sugg J, Haas GP, Higano CS
doi: 10.1038/s41391-021-00465-7
Uro-Oncology
Systemic treatment for metastatic castrate resistant prostate cancer: Does seqence matter?
Prostate.
Andrews JR, Ahmed ME, Karnes RJ, Kwon E, Bryce AH
doi: 10.1002/pros.23954.
COMMENTED
Uro-Oncology
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019
★ 2
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
doi: 10.1016/j.eururo.2020.01.012.